Happy Nice Mall

Johnson & Johnson said the Covid vaccine is effective against the highly contagious Delta variant, adding to the growing evidence that it protects against the most dangerous variants of the most widely available Covid vaccines.

Even eight months after vaccination, one shot J.&J. The vaccine is proving to be highly effective against Delta, a reassuring finding for the 11 million Americans who are vaccinated, and for countries around the world who are betting on getting the vaccine, the company reported on Thursday. In the United States, the variant first identified in India now accounts for an estimated one in four new cases and CDC listed in 23 states.

Johnson & Johnson said its vaccine showed a small decrease in potency against the Delta variant compared to its effectiveness against the original virus, and a greater decrease against the Beta variant, which was first identified in South Africa. This is the same pattern seen in mRNA vaccines made by Pfizer-BioNTech and Moderna.

Intense rhetoric about Delta’s threat has left some vaccinated people feeling anxious about whether they are protected. The global spread of the variant has imposed new restrictions from Ireland to Malaysia.

It was disappointing that the effectiveness of the Johnson & Johnson vaccine against Delta was not clear. And reports of a number of cases, among them Players on the Yankees baseball team The person who received the Johnson & Johnson vaccine, though all asymptomatic or mild, did nothing to allay fears.

Studies have shown that Delta and Beta variants slightly reduce the effectiveness of Pfizer and Moderna vaccines. For Pfizer, research shows that two doses provide 88 percent protection against the Delta variant, just under 93 percent protection against Alpha. The Moderna vaccine has performed similarly to Pfizer’s in previous studies.

Johnson & Johnson collected less data on vaccines than its peers, and the study published Thursday was small and has not yet been published in a scientific journal. Updates on the efficacy of the Johnson & Johnson vaccine have been slow as it became available later than the Pfizer and Moderna vaccines in the US. The vaccine provided about 72 percent protection against early versions of the virus.